Trial
NCT00306670
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
Genentech, Inc.
Condition
Hemophilia A
Intervention
Rituxan
Why stopped
Sponsor no longer funding study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-10